Australian Clinical Labs Ltd (ASX: ACL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Australian Clinical Labs Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $465.17 million
P/E Ratio 14.31
Dividend Yield 5.12%
Shares Outstanding 192.22 million
Earnings per share 0.171
Dividend per share 0.13
Year To Date Return -11.27%
Earnings Yield 6.99%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Australian Clinical Labs Ltd (ASX: ACL)
    Latest News

    impacts on newcrest share price by merger represented by two people bringing together jigsaw pieces against gold background
    Broker Notes

    2 ASX shares that could EXPLODE when their M&A deals are done

    A business can change overnight after a corporate buyout. Here are two stocks QVE analysts are excited about on that…

    Read more »

    Three rock climbers hang precariously off a steep cliff face, each connected to the other with the higher person holding on and the two below them connected by their arms and rope but not making contact with the cliff face.
    Earnings Results

    3 ASX All Ords shares falling hard on earnings updates

    It's a hard day to be a shareholder of these companies.

    Read more »

    A telehealth doctor at her desk.
    Healthcare Shares

    Fundie reveals ASX 300 healthcare stock trading at 40% discount to peers

    This healthcare share could be dirt cheap according to one fund manager.

    Read more »

    A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
    Dividend Investing

    3 magnificent ASX dividend shares that could turn $5k into $50,000

    Growth stocks aren't the only way to a massive windfall. Here's a trio I think that could also take you…

    Read more »

    A woman gives a side eye look with her lips pursed as though she might be saying ooh at something she's hearing or learning for the first time.
    Dividend Investing

    12 ASX dividend shares with yields over 10%. Are they too good to be true?

    Is a 10% yield a good or a bad sign for an income share?

    Read more »

    Two happy scientists analysing test results in a lab
    Healthcare Shares

    Which ASX All Ords healthcare share has a 20% dividend yield?

    Why is this small-cap company's gross trailing dividend yield so high, and is it sustainable?

    Read more »

    A man points at a paper as he holds an alarm clock, indicating the ex-dividend date is approaching.
    Dividend Investing

    8 ASX All Ords shares trading ex-dividend this week

    These ASX shares will soon allocate their upcoming dividends to shareholders.

    Read more »

    A telehealth doctor at her desk.
    Healthcare Shares

    Why this ASX All Ords healthcare share is defying the market weakness and zooming higher

    Australian Clinical Labs has made a bold takeover approach for its larger rival.

    Read more »

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    Healius share price jumps 7% on takeover approach from smaller rival

    Could Healius about to be taken over by a smaller rival?

    Read more »

    Two boys with cardboard rockets strapped to their backs, indicating two ASX companies with rocketing share prices
    Share Gainers

    Catch these fast-rising 2 ASX shares before it's too late: Celeste

    This pair of stocks rocketed up in February during reporting season, but are still great value for those willing to…

    Read more »

    three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
    Small Cap Shares

    'Very attractive valuations': Experts name 3 small-cap ASX shares to buy

    If you agree that smaller companies are ready to roar again in 2023, here is a trio of stocks to…

    Read more »

    A older man and younger man rest, exhausted but happy after a good boxing session.
    Cheap Shares

    2 hammered ASX shares to buy before they rise again: Celeste

    If you're purchasing a house you'd want it for the lowest price. So why is it any different for stocks?

    Read more »

    Frequently Asked Questions

    Yes, Australian Clinical Labs has historically paid two fully franked shareholder dividends a year.

    Australian Clinical Labs generally pays its shareholder dividends in April and September.

    Australian Clinical Labs Ltd listed on the ASX on 14 May 2021.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    01 Sep 2025 $0.0900 100.00% Final 23 Sep 2025
    27 Mar 2025 $0.0350 100.00% Interim 16 Apr 2025
    04 Sep 2024 $0.0900 100.00% Final 27 Sep 2024
    28 Mar 2024 $0.0300 100.00% Interim 26 Apr 2024
    27 Mar 2023 $0.0700 100.00% Interim 26 Apr 2023
    23 Aug 2022 $0.4100 100.00% Final 15 Sep 2022
    25 Mar 2022 $0.1200 100.00% Interim 21 Apr 2022

    ACL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Australian Clinical Labs Ltd

    Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.

    Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing. 

    In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.

    ACL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Feb 2026 $2.42 $-0.02 -0.82% 625,611 $2.44 $2.46 $2.37
    12 Feb 2026 $2.44 $-0.07 -2.79% 701,943 $2.53 $2.53 $2.42
    11 Feb 2026 $2.51 $0.00 0.00% 383,075 $2.55 $2.55 $2.49
    10 Feb 2026 $2.51 $0.06 2.45% 690,354 $2.46 $2.54 $2.46
    09 Feb 2026 $2.45 $-0.13 -5.04% 2,426,988 $2.67 $2.67 $2.45
    06 Feb 2026 $2.58 $-0.15 -5.49% 1,032,670 $2.74 $2.74 $2.57
    05 Feb 2026 $2.73 $0.05 1.87% 233,990 $2.72 $2.75 $2.69
    04 Feb 2026 $2.68 $-0.10 -3.60% 804,463 $2.78 $2.83 $2.68
    03 Feb 2026 $2.78 $-0.01 -0.36% 693,435 $2.80 $2.86 $2.76
    02 Feb 2026 $2.79 $0.06 2.20% 837,679 $2.69 $2.81 $2.69
    30 Jan 2026 $2.73 $0.04 1.49% 1,026,126 $2.70 $2.75 $2.68
    29 Jan 2026 $2.69 $0.02 0.75% 463,328 $2.71 $2.74 $2.63
    28 Jan 2026 $2.67 $-0.04 -1.48% 762,184 $2.74 $2.74 $2.63
    27 Jan 2026 $2.71 $0.06 2.26% 766,030 $2.63 $2.78 $2.61
    23 Jan 2026 $2.65 $-0.02 -0.75% 257,942 $2.61 $2.66 $2.61
    22 Jan 2026 $2.67 $0.07 2.69% 597,517 $2.57 $2.68 $2.57
    21 Jan 2026 $2.60 $0.03 1.17% 1,289,130 $2.55 $2.60 $2.54
    20 Jan 2026 $2.57 $0.03 1.18% 241,056 $2.54 $2.57 $2.53
    19 Jan 2026 $2.54 $-0.10 -3.79% 471,627 $2.67 $2.67 $2.53
    16 Jan 2026 $2.64 $-0.03 -1.12% 191,167 $2.70 $2.70 $2.62
    15 Jan 2026 $2.67 $0.02 0.75% 416,803 $2.66 $2.67 $2.65

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Oct 2025 Stephen Roche Buy 70,000 $193,900
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Stephen Patrick Roche Non-Executive DirectorNon-Executive Chairman Jun 2025
    Mr Roche has strategic and operational experience across several industry sectors including healthcare, retail, building materials and fast-moving consumer goods. Stephen has over 15 years' experience as a director of public companies, not-for-profits and private family offices, having held executive roles as the Managing Director and CEO of Australian Pharmaceutical Industries Limited and Bridgestone Australia & New Zealand. Stephen is currently a Director of the Adelaide Football Club. Stephen was formerly a Non-Executive Director of Myer Family Investments Ltd. He also established and was Chair of the Priceline Sisterhood Foundation from 2015, before retiring in 2018. The foundation, with its mission of creating positive health outcomes and support for women, became the official charity for all Wesfarmers Health businesses from 2025.
    Ms Christine Nildra Bartlett Non-Executive Director Aug 2023
    Ms Bartlett is an experienced Non-Executive Director, with executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a commercial perspective, in fostering innovation and leveraging new emerging technologies. Christine is currently the Chair of CEDA and a Non-Executive Director of Mirvac Limited, TAL Life Limited and Reliance Worldwide Corporation Limited. Christine is a member of the UNSW Australian School of Business Advisory Council. Christine has previously held Non-Executive Director roles with iCare NSW, Clayton Utz, GBST Holdings Limited, The Smith Family and Sigma Healthcare Limited. She is member of Risk Committee.
    Mr Mark Haberlin Non-Executive Director Apr 2021
    Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is chair of Risk Committee.
    Ms Melinda Leigh McGrath Chief Executive OfficerExecutive Director Dec 2020
    Ms McGrath has more than 30 years' experience in healthcare with over 25 years of experience in chief executive roles and over 15 years of experience in pathology CEO roles. Melinda has led the organisation's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Melinda was Chief Executive Officer of QML Pathology (part of Healius/ Primary Healthcare) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held transformative chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services and a superannuation fund, UC Super.
    Ms Sarah Butler Non-Executive Director Feb 2025
    Ms Butler has experience in health, insurance, government, consumer and technology industries with a long career in strategy consulting with Booz & Company and subsequently at PwC. Sarah has worked as a strategic advisor in more than 30 countries, including five years spent living and working in China and Asia. Sarah is currently a Non-Executive Director of Lumonus (global healthtech), Insurance Manufacturers of Australia (being a joint venture of IAG and RACV) and The George Institute for Global Health, where she is also the Chair of the People Committee.
    Mr Grant Jeffery Non-Executive Director Feb 2025
    Mr Jeffery has experience in healthcare, aerospace and security services, across public and private companies, having held multiple CEO roles across international businesses based in New York, Singapore, California and Sydney. Prior to his corporate career, Grant served as an Officer in the Royal Australian Air Force for 10 years holding leadership roles across functional disciplines. Grant is currently the Chair and Non-Executive Director of Brighter Life Group and an Executive Director of BGI Advisory Services as well as a Board advisor to Dokotela. He is member of Risk Committee.
    Ms Eleanor Padman Company Secretary
    -
    Matthew Cordingley Chief Financial Officer
    -
    Eleanor Padman Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 56,401,782 28.81%
    HSBC Custody Nominees (Australia) Limited 49,496,460 25.28%
    J P Morgan Nominees Australia Pty Limited 31,611,161 16.15%
    BNP Paribas Nominees Pty Ltd 5,010,540 2.56%
    National Nominees Limited 2,969,871 1.52%
    UBS Nominees Pty Limited 2,670,859 1.36%
    Melinda McGrath 2,173,867 1.10%
    Neweconomy Com Au Nominees Pty Limited 2,144,321 1.10%
    BNP Paribas Nominees Pty Ltd i 1,508,979 0.77%
    Warbont Nominees Pty Ltd 1,469,081 0.75%
    Merrill Lynch (Australia) Nominees Pty Limited 1,421,218 0.73%
    Ecapital Nominees Pty Limited 1,352,591 0.70%
    ACL Employee Share Trusco Pty Ltd 1,268,956 0.65%
    HSBC Custody Nominees (Australia) Limited i 836,267 0.43%
    Zachary Investments Pty Ltd 800,000 0.41%
    Anthony Friedli 754,390 0.39%
    A.C.N. 633 176 100 Pty Ltd 749,464 0.38%
    HSBC Custody Nominees (Australia) Limited GSI EDA 612,905 0.31%
    HSBC Custody Nominees (Australia) Limited Gsco Eca 572,267 0.29%
    Pacific Custodians Pty Limited 550,845 0.28%

    Profile

    since

    Note